Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What To Look Out For In The Latest Eiger Biopharmaceuticals Inc (EIGR) Trial

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) just announced first dosing in its phase II LIBERTY trial, and markets seem to have turned a blind eye to the development. The company is down a percentage point ahead of Tuesday’s open in the US, trading for a market cap of a little over $134 million.

There’s every chance markets are waiting on data from the trial before committing to a bias. With this in mind, and ahead of any interim updates, let’s take a look at the drug in question and try and figure out what impact it might have on Eiger going forward.

The drug is called ubenimex, or bestatin, and it’s part of a family of drugs called leukotriene inhibitors. In the phase II Eiger just kicked off, it has a target indication of pulmonary arterial hypertension, but it’s already approved in Japan as an adjunct to chemotherapy. It’s administered alongside whatever chemotherapy drug a patient is receiving, and designed to improve the efficacy of the latter. So why go after a PAH indication in the US? Well, a specific type of leukotriene, LTB4, is thought to be linked to inflammation, and the inflammation is the root cause of PAH. LTB4 is produced by what’s called leukotriene A4 hydrolase, and ubenimex inhibits leukotriene A4 hydrolase. Through this inhibition, Eiger is hoping it can delay or stop the production of LTB4, the body’s inflammatory response to this production, and in turn, treat PAH.

pharmacist, senior, man, talking, helpful, nhs, helping, counter, medication, older, american, drugs, woman, shelves, male, pack, usa, medical, practice, horizontal, adult,

Monkey Business Images/Shutterstock.com

The trial that just kicked off is a multi-center, randomized, double-blind, placebo-controlled trial, with all patients PAH sufferers. Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) is aiming to bring 45 patients into the study, of which two out of three will receive ubenimex, while the remaining third will receive placebo. It’s a twenty-four-week trial, with a twenty-four-week extension period. The primary endpoint is a change from baseline in what’s called pulmonary vascular resistance (PVR). PVR is a calculation used by physicians to diagnose and monitor PAH, and its based on a combination of three factors – mean pulmonary artery pressure, left atrial pressure and pulmonary flow. The results are measured in a unit called dynes-sec-cm-5, and in the data release we are looking for a reduction from the baseline number. Normal PVR is circa 67, with a +-30 dynes-sec-cm-5, so ideally we’re looking for patients that kicked off the trial with a high PVR, and registered as close to 67 as possible come the 24-week measurement point (and beyond that, maintained this reduction to the second 24 week extension measurement point).

What’s the market like for this sort of treatment? Well, the PAH therapeutic space is worth around $3.5 billion right now, and analysts expect this to run at a CAGR of circa 3% between now and 2024, giving the condition a forward market size of $4.75 billion. Current treatments don’t target the inflammation associated with the condition, so if Eiger can demonstrate efficacy in reducing or removing this inflammation, it would have a good chance at rapid double digit market penetration.

So what are we looking for going forward? Well, the trial in question is set to wrap up in September next year, but there should be plenty of opportunities to garner insight into the status of the trial between now and then. It’s reasonable to assume that once the 45 patient target has been reached we’ll see an update, and this might be a minor upside catalyst, but the real catalyst will be on interim once the 45 patients have completed their first round of 24 weeks’ worth of dosing. At that point, Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will have a pretty solid data set, and should serve up some interim figures. Any reduction in PVR from baseline would be good, with the higher the reduction the higher the impact in terms of upside we are likely to see. There are a few secondaries in play, and of these, the headline is probably the six-minute walk test, so keep an eye out for an improvement from baseline on this one as a kicker to the primary efficacy endpoint.

All said, it’s going to be an interesting six months for the company. If it can present us with some interim that suggests efficacy, speculative capital will likely flow in ahead of topline. One to keep an eye on. Cautiously, but well worth a look.

Follow Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR)
Trade (NASDAQ:EIGR) Now!

Note: This article is written by Mark Collins and was originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!